Coronary in Medical Technology

Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients

... graft patency in patients undergoing off-pump coronary artery bypass (OPCAB). Pre-heparinization was ... an endoscope is passed and the vein harvested for coronary artery bypass graft (CABG) procedures. This ... excellent patency results in patients who require coronary artery bypass grafting, reinforcing the efficacy ...

Cardiogenesis Announces Presentation of its PHOENIX(R) Combination TMR Plus Stem Cell Delivery System at the International Society of Minimally Invasive Cardiothoracic Surgeons (ISMICS) Annual Meeting

... Seven patients had concomitant coronary bypass grafting, one patient stand alone therapy. ... Laser Revascularization for Diffuse Nongraftable coronary Artery Disease" can be located at: ... for Treating Refractory Angina Due to Diffuse coronary Heart Disease", reinforce the company's ...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease

... trial. The results found that percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(R) Paclitaxel-Eluting coronary Stent System was consistently associated with ... during the first year after treatment compared to coronary artery bypass graft (CABG) surgery. Total ...

Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent

... chromium TAXUS(R) Element(TM) Paclitaxel-Eluting coronary Stent System in select markets worldwide. The ... chromium alloy engineered specifically for coronary stent applications and represents the Company's ... performance in treating patients with complex coronary artery disease. The Company is anticipating CE ...

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

... the re-narrowing of arteries after percutaneous coronary intervention (PCI). The article reported that ... the risk of repeat procedures. The Swedish coronary Angiography and Angioplasty Registry holds data ... Stent as well as the PROMUS(R) Everolimus-Eluting coronary Stent. We look forward to introducing our ...

Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome

... today that FRANCIS (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation ... to patients within 96 hours of an Acute coronary Syndrome (ACS) event, met its primary endpoint of ... in C-reactive protein. About Acute coronary Syndrome ...

InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients

... '09 in May in Barcelona. About MGuard(TM) coronary MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection. The ... structural integrity of the stent. The MGuard(TM) coronary stent provides permanent embolic protection, ...

New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel

... In prasugrel-treated patients with acute coronary syndromes (ACS) who underwent an artery-opening procedure known as percutaneous coronary intervention (PCI), the incidence of the combined ... and fatal bleeding.(3) About Acute coronary Syndromes ...

Schering-Plough Announces Results of the Early ACS Trial

... Provisional Use in Patients with High-Risk Acute coronary Syndrome, Study Finds KENILWORTH, N.J., ... (eptifibatide) routinely in patients with Acute coronary Syndrome (ACS), at least 12 hours prior to ... Inhibition in Non-ST-Segment Elevation Acute coronary Syndrome (EARLY ACS) study, which was designed to ...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

... advantages of the XIENCE V(R) Everolimus Eluting coronary Stent System continued to increase between two ... to the TAXUS(R) Express2(TM) Paclitaxel-Eluting coronary Stent System / TAXUS(R) Liberte(TM) Paclitaxel-Eluting coronary Stent System (TAXUS). Both TAXUS Express2 (73 ...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease

... the overall cost effectiveness of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery varied ... than CABG in patients with low or moderate coronary lesion complexity. CABG was more cost effective ...

Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial

... of the company's fully bioabsorbable drug eluting coronary stent. This second phase of the ABSORB clinical ... show that bioabsorbable devices are the future of coronary artery disease treatment." Results from ... everolimus eluting stent successfully treated coronary artery disease, and that at two years, the ...

Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

... adverse cardiovascular events following an Acute coronary Syndrome (ACS) event." About A-001 A-001 ... 2007. About varespladib (A-002) and Acute coronary Syndrome A-002 (varespladib) is a potent ... A-002 is being examined in patients with acute coronary syndrome (ACS) for a reduction in secondary MACE. ...

The Lancet Publishes Two-Year Results of Abbott's Fully Bioabsorbable Drug Eluting Stent

... currently in development, successfully treated coronary artery disease and was absorbed into the walls of ... evaluating a fully bioabsorbable drug eluting coronary stent, and advanced imaging methods were used to ... a major breakthrough in the treatment of narrowed coronary arteries. The two-year ABSORB trial results show ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

... clopidogrel) for patients undergoing percutaneous coronary intervention (PCI), commonly known as balloon ... the Thrombin Receptor Antagonist Percutaneous coronary Intervention (TRA-PCI) trial was the rate of ... along with subsequent data from Phase II acute coronary syndromes (ACS) and stroke studies conducted in ...

Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield

... No Peri-procedural Complications Reported With coronary Device DOYLESTOWN, Pa., March 4 /PRNewswire/ ... in the study had non-calcified lesions in coronary arteries, lesions that would normally be treated ... balloon-expandable stents. No major adverse coronary events (MACE) were reported at 30 days ...

Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study

... study endpoints were major coronary events (primary) and total cardiovascular events ... in nonfatal MI (P=0.01) and 21% reduction in coronary revascularisation (P=0.003).(5) There was ... low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll ...

New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial

... Journal of Medicine. In the study, percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(TM) Paclitaxel-Eluting coronary Stent System was compared to contemporary coronary artery bypass graft (CABG) surgery in patients ...

Risk of Stroke, Heart Disease in Women Lowered by Mediterranean Diet

... and fish -- are at a lower risk for stroke and coronary heart disease, according to a study published ... follow-up, researchers found 2,391 incidents of coronary heart disease, 1,763 strokes and a combined total ... Institute -- significantly lowered their risk of coronary heart disease and stroke. The DASH diet is high ...

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents

... TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting coronary Stent System and its TAXUS Liberte Long(TM) Paclitaxel-Eluting coronary Stent System. If approved, the TAXUS Liberte ... vessel in-stent restenosis and major adverse coronary events (MACE) in patients treated with the TAXUS ...

Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent

... PROMUS(TM) Element(TM) Everolimus-Eluting coronary Stent. The first U.S. patient was enrolled last ... compare the PROMUS Element Everolimus-Eluting coronary Stent to the PROMUS(TM) Everolimus-Eluting coronary Stent. The Company plans to develop additional ...

Mayo Clinic Study Finds Younger Men With Erectile Dysfunction at Double Risk of Heart Disease

... of heart disease. "The highest risk for coronary heart disease was in younger men," says ... dysfunction a harbinger of future risk of coronary heart disease -- and take appropriate steps to ... were 80 percent more likely to develop coronary heart disease compared to men without erectile ...

New Research Suggests Platelet 'Stickiness' May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease

... including heart attack, in patients treated with coronary artery stents. "We currently measure the ... of complications, including heart attack, after coronary artery stenting. Their work is helping to ... the testing and treatment of patients with coronary artery disease, offering further evidence that a ...

Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent

... evaluating the XIENCE V(TM) Everolimus Eluting coronary Stent System demonstrated that Abbott's ... the TAXUS(R) Express2(TM) Paclitaxel-Eluting coronary Stent System (TAXUS) in reducing major ... About XIENCE V XIENCE V is used to treat coronary artery disease by propping open a narrowed or ...

Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference

... Phase 3 trial of darapladib underway in chronic coronary heart disease - - HGS provides 2009 ... darapladib in men and women with chronic coronary heart disease. Darapladib was discovered by GSK ... "Despite major advances in medical treatment, coronary heart disease remains the leading cause of death ...

CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial

... II clinical trial for the treatment of severe coronary heart disease. The sites are Minneapolis Heart ... trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized ... CVBT's ACORD (Angiogenesis for the treatment of coronary heart Disease) trial for the treatment of ...

CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease

... II clinical trial to treat patients with severe coronary heart disease. The ACORD (Angiogenesis for the treatment of coronary heart Disease) trial will include four ... doses in approximately 120 patients with severe coronary heart disease. Thirty sites are expected ...

Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death

... first three months after hospital admission for coronary artery disease compared with those who did not ... study analyzed 15,604 patients with significant coronary heart disease undergoing diagnostic ... groups at Daiichi Sankyo and Lilly. About coronary Heart Disease As one of the primary forms of ...

Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application

... agent for the treatment of patients with acute coronary syndromes (ACS) who are being managed with an ... hypertension, diabetes, and acute coronary syndrome. Equally important to the company is the ... versus Clopidogrel in Patients with Acute coronary Syndromes. New England Journal of ...

SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery

... its landmark SYNTAX trial comparing percutaneous coronary intervention (PCI) using the TAXUS(R) Express2(TM) Paclitaxel-Eluting coronary Stent System to contemporary coronary artery bypass graft (CABG) surgery. The results ...

Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System

... in patients undergoing elective percutaneous coronary intervention (PCI). REG1 is a ... REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures. These procedures, ...

Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years

... that the XIENCE V(TM) Everolimus Eluting coronary Stent System continues to deliver clinically ... to the TAXUS(R) paclitaxel-eluting coronary stent system out to two years. In this ... About XIENCE V XIENCE V is used to treat coronary artery disease by propping open a narrowed or ...

12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions

... (76 lesions) treated with the CATANIA(TM) coronary Stent System with NanoThin Polyzene(R)-F surface ... due to de novo, obstructive lesions of native coronary arteries. The trial was sponsored by CeloNova ... Color-Advanced Microspheres and the CATANIA(TM) coronary Stent System with NanoThin Polyzene(R)-F. Neither ...

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent

... New coronary stent features thin struts designed for more ... at 61 sites, comparing patients with de novo coronary lesions treated with the TAXUS Liberte Stent to a ... TAXUS Express2(TM) Atom(TM) Paclitaxel-Eluting coronary Stent System for use in vessels as small as 2.25 ...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

... TAXUS(R) Liberte(R) Paclitaxel-Eluting coronary Stent Systems, including 12-month subset data on ... the SYNTAX trial, which compares percutaneous coronary intervention (PCI) using the TAXUS Express2 Stent System to coronary artery bypass graft (CABG) surgery in these most ...

TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System

... system specially designed for use at or near coronary bifurcations. Representing the next generation ... in the treatment of patients suffering from coronary artery disease at or near bifurcations. "I like ... Lesions at or near side branches in the coronary tree pose multiple challenges to interventional ...

Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent

... Element(TM) paclitaxel-eluting coronary stent. The PERSEUS clinical program has enrolled ... the Use of the TAXUS Element Paclitaxel-Eluting coronary Stent System for the Treatment of De ... control (TAXUS V de novo bare-metal Express(R) coronary Stent System). This study will include ...

Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval

... the opportunity to help patients with recent coronary events." "The regulatory clarity in the United ... patient FRANCIS trial (Fewer Recurrent Acute coronary events with Near-term Cardiovascular Inflammation ... duration of the six-month trial. About Acute coronary Syndrome ...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

... an artery-opening procedure known as percutaneous coronary intervention (PCI), or if they occurred ... (up to 15 months) in 13,608 acute coronary syndromes (ACS) patients who were managed with ... Heart attacks are a major manifestation of coronary heart disease, a global health problem. About 7.2 ...

Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008

... response also was seen in patients with stable coronary artery disease, thereby confirming ... in 26 patients undergoing elective percutaneous coronary intervention (PCI). The multi-center, ... REG1 for use in patients suffering from acute coronary syndrome who undergo coronary revascularization ...